-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Mastocytosis is a hematopoietic tumor characterized by the expansion and accumulation of tumor mast cells (MCs) in one or more organ systems , including bone marrow (BM), skin, liver, spleen, and gastrointestinal (GI) ) Channel
.
In most patients with systemic mastocytosis (SM), activating mutations of KIT gene (mainly D816V) are detected in tumor cells
Mastocytosis is a kind of hematopoietic tumor, which is characterized by the expansion and accumulation of tumor mast cells (MCs) in one or more organ systems , including bone marrow (BM), skin, tumor mast cells (MCs) in one or Expansion and accumulation in multiple organ systems The expansion and accumulation of tumor mast cells (MCs) in one or more organ systems includes bone marrow (BM), skin, liver, spleen, and gastrointestinal (GI) channels
Foreign research teams have conducted a deeper understanding of the poor prognostic factors of WHO-based BMM patients in the ECNM registry data set, and compared whether BMM has these risk factors and the characteristics and characteristics of typical ISM with skin lesions (ISMtyp).
Ending
.
The specific purpose of the research is to improve and update the diagnostic criteria for true BMM
Foreign research teams have conducted a deeper understanding of the poor prognostic factors of WHO-based BMM patients in the ECNM registry data set, and compared whether BMM has these risk factors and the characteristics and characteristics of typical ISM with skin lesions (ISMtyp).
In the registered data set of the European Competence Network, they compared the characteristics and outcomes of 390 BMM patients with 1175 typical ISM patients
These data support the recommendation to define BMM as a separate SM variant, which is characterized by SM criteria, no skin damage, no b-sign, and trypsin level <125 ng/mL
Original source:
Original source:Zanotti, R.
Zanotti, R.
Leave a message here
